Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

You Should Stand Up Straight, for All Sorts of Reasons

by Team Lumida
October 28, 2025
in Health and Longevity
Reading Time: 5 mins read
A A
0
You Should Stand Up Straight, for All Sorts of Reasons
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

Powered by lumidawealth.com

  • Good posture improves circulation, respiration, digestion, bladder function, cognitive ability, and mood; reduces stress/anxiety and boosts self-esteem per research spanning 20+ years.
  • Head weighs 10-12 lbs in neutral position but exerts 49 lbs of force at 45-degree tilt (typical phone-viewing angle); proper alignment prevents strain and maintains physical fitness/independence with aging.
  • Physical therapists say improving posture requires more than core strength—needs full-body flexibility/strength balance. Dynamic stretching (Tai Chi) may be more effective than static stretching (yoga) for postural issues.
  • Self-assessment tools: stand against wall (head, shoulders, buttocks touching), use mirrors at multiple angles, recruit friends for photos/videos. Apps like Posture Reminder, Upright, PosturePal use motion-sensing to alert slouching.

What Happened?

Good posture—an erect, balanced bearing—improves circulation, respiration, digestion, bladder function, cognitive ability, and mood, with research showing a bidirectional relationship between depression and slumped posture. Proper alignment prevents strain and maintains physical fitness/independence with aging; geriatricians say stooping isn’t inevitable—many 90- and 100-year-olds have “beautiful posture” by paying attention. The head weighs 10-12 lbs in neutral position but exerts 49 lbs of force at 45-degree tilt (typical phone-viewing angle).

Physical therapists say improving posture requires more than core strength—needs full-body flexibility/strength balance, like ballet dancers who train for erect bearing. Self-assessment tools include standing against a wall (head, shoulders, buttocks touching), using mirrors at multiple angles, and recruiting friends for photos/videos to reveal 3D postural irregularities. Dynamic stretching (Tai Chi, Essentrics) may be more effective than static stretching (yoga) for postural issues. Research shows upright posture reduces stress/anxiety, boosts self-esteem, improves cognitive performance, and increases speech rate. Apps like Posture Reminder, Upright, and PosturePal use motion-sensing to alert slouching. Physical therapists can evaluate posture and develop tailored regimes; it’s never too late to improve.

Why It Matters

Poor posture is a widespread but underappreciated health issue with cascading physical and mental effects. For individuals, chronic slouching (exacerbated by phone use and sedentary work) leads to musculoskeletal strain, reduced cognitive function, and mood disorders—impacting productivity and quality of life. The 49 lbs of force from phone-viewing posture explains rising neck/back pain, especially among younger demographics. For healthcare systems, posture-related issues drive demand for physical therapy, pain management, and geriatric care as aging populations face mobility loss.

The bidirectional relationship between posture and mental health (depression, anxiety) suggests posture interventions could complement or reduce reliance on pharmaceutical treatments. For employers, poor posture among workers (especially remote/desk workers) contributes to absenteeism, lower productivity, and higher healthcare costs. The rise of posture-tracking apps and wearables (Upright, PosturePal) signals a growing market for digital health solutions targeting ergonomics and wellness. For investors, opportunities exist in physical therapy services, ergonomic furniture/equipment, wearable tech, and wellness apps as awareness grows.

What’s Next

Watch for increased adoption of posture-tracking wearables and apps as remote work persists and phone use remains high. Monitor growth in physical therapy demand, especially among younger demographics with tech-induced posture issues. Track corporate wellness programs incorporating posture assessments and ergonomic interventions to reduce healthcare costs. For digital health, watch for AI-powered posture correction tools integrated into smartwatches, fitness trackers, or workplace software. Monitor research linking posture to mental health outcomes—could drive new treatment protocols or insurance coverage for posture therapy. For furniture/equipment makers, watch demand for ergonomic desks, chairs, and accessories as employers prioritize worker health. Risks: low consumer awareness, resistance to behavior change, or skepticism about posture’s health impact. Catalysts: high-profile studies linking posture to productivity/longevity, employer mandates for ergonomic workspaces, or insurance coverage for posture therapy. Favor digital health platforms, ergonomic equipment makers, and physical therapy providers.

Source
Previous Post

Dormant Iowa Nuclear Plant Poised to Power Google’s Energy Needs

Next Post

Trump Hails Golden Era in Japan Relations

Recommended For You

$399 Signal Ring Claims to Replace the Blood Pressure Cuff — No Calibration, No Subscription, Clinical Trial at Stanford

by Team Lumida
1 day ago
Fingers hold a black smart ring with circuits visible.

Vital Signals, a three-year-old startup, has launched a $399 Signal Ring that claims to track blood pressure as accurately as a traditional arm cuff — without requiring any...

Read more

Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

by Team Lumida
3 days ago
Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

Novo Nordisk's Wegovy pill has seized 89% of new oral obesity pill prescriptions since its January 2026 launch, leaving Eli Lilly's Foundayo — launched in April — with...

Read more

Information Blocking in Healthcare Is Down — But a Stubborn Minority of IT Vendors Keep Doing It Routinely

by Team Lumida
4 days ago
doctor holding red stethoscope

The share of health information exchanges reporting instances of information blocking fell from over 90% in 2019 to 71% in 2025, according to new ONC data — but...

Read more

Novo Nordisk Squeezes Suppliers for Discounts as Eli Lilly Eats Its Lunch in the Obesity Drug Market

by Team Lumida
2 weeks ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk has written to suppliers seeking price discounts to protect its cost base as it fights to claw back market share lost to Eli Lilly in the...

Read more

Medicare Launches $50/Month Weight-Loss Drug Coverage Today — With Caveats

by Team Lumida
2 weeks ago
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

Medicare's "Bridge" program kicks off July 1, offering Wegovy and Zepbound to 12.5–20 million eligible seniors at a $50 monthly copay — down from up to $450 cash...

Read more

FDA Reverses Rejection of Regenxbio Gene Therapy for Fatal Rare Disease

by Team Lumida
4 weeks ago
FDA Reverses Rejection of Regenxbio Gene Therapy for Fatal Rare Disease

The FDA agreed to reverse its rejection of Regenxbio's Navsunli gene therapy for Hunter syndrome — the third rare-disease drug reversal under new FDA leadership, marking a retreat...

Read more

Nvidia Partners With Abridge to Build an AI Model Trained on Real Doctor-Patient Conversations

by Team Lumida
1 month ago
Nvidia’s AI Demand Surge: Hon Hai Ramps Up Server Production

Nvidia and AI medical note-taking startup Abridge are jointly developing a clinical AI model trained on de-identified doctor-patient conversations, using Nvidia's open Nemotron models as a base —...

Read more

Nearly 90% of Americans Have It and Don’t Know It: First Guidelines Issued for CKM Syndrome

by Team Lumida
1 month ago
people holding us a flag during daytime

The American Heart Association and three major medical societies published the first clinical guidelines for cardiovascular-kidney-metabolic syndrome — a cluster of interconnected conditions tied to excess body fat...

Read more

Employers Are Slashing GLP-1 Coverage as Costs Spiral — And Some Are Adding Weigh-Ins to Keep It

by Team Lumida
1 month ago
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

More than a quarter of large companies are adding new criteria for GLP-1 weight-loss coverage while 11% are dropping it altogether, as drug costs balloon and employers struggle...

Read more

GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

by Team Lumida
1 month ago
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

Shoppers on weight-loss drugs are dropping a clothing size every month, flooding retailers with returns — one online suit seller saw a 50% jump — and forcing the...

Read more
Next Post
Why Berkshire’s Latest Yen Bond Sale Could Ignite the Japanese Market

Trump Hails Golden Era in Japan Relations

Trump Tariffs Leave Key Questions on China Supply Chain Rules Unanswered

After Demolishing the U.S.-China Relationship, Trump Is Rebuilding It His Way

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

poached egg with vegetables and tomatoes on blue plate

Diet Is the Biggest Longevity Lever Most People Underuse

February 5, 2026
Nvidia Loses $220 Billion: What It Means for Your Investments

xAI to Raise $20 Billion After Nvidia and Others Boost Round

October 8, 2025
keys on hand

Luxury Real Estate Agents Share Tales of Family Drama Disrupting Million-Dollar Deals

December 21, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018